Abstract: A method may include providing a treatment fluid comprising a metal sulfide dissolver and a base fluid. The metal sulfide dissolver includes a chelating agent, a boosting agent, a scaling agent, and a dispersing agent. The treatment fluid is then injected to contact a metal sulfide scale, which dissolves at least partially. The treatment fluid may be injected into a wellbore as a standalone treatment or as an additive.

Abstract: A method may include providing a treatment fluid comprising a metal sulfide dissolver and a base fluid. The metal sulfide dissolver includes a chelating agent, a boosting agent, and a dispersing agent. The treatment fluid is then injected to contact a metal sulfide scale, which dissolves at least partially. The treatment fluid may be injected into a wellbore as a standalone treatment or as an additive.

Abstract: A method may include providing a treatment fluid comprising a metal sulfide dissolver and a base fluid. The metal sulfide dissolver includes a chelating agent, a boosting agent, a scaling agent, and a dispersing agent. The treatment fluid is then injected to contact a metal sulfide scale, which dissolves at least partially. The treatment fluid may be injected into a wellbore as a standalone treatment or as an additive.

Abstract: Methods can include contacting an aqueous fluid including a zirconium salt with a scale inhibitor in a subterranean formation to form a zirconium salt/scale inhibitor complex, and systems related thereto.

Abstract: A method, system and computer-readable medium for assessing a disease condition of a cancer of a subject, including: receiving a blood sample from the subject; isolating a plurality of circulating tumor cells (CTCs) from the blood sample; measuring at least one of cell or cell nucleus sizes of each of the plurality of CTCs; determining a measured CTC size distribution of the plurality of CTCs based on the measuring; comparing the measured CTC size distribution to a reference CTC size distribution using a computer; and assigning the disease condition of the cancer of the subject based on the comparing.

Abstract: A method, system and computer-readable medium for assessing a disease condition of a cancer of a subject, including: receiving a blood sample from the subject; isolating a plurality of circulating tumor cells (CTCs) from the blood sample; measuring at least one of cell or cell nucleus sizes of each of the plurality of CTCs; determining a measured CTC size distribution of the plurality of CTCs based on the measuring; comparing the measured CTC size distribution to a reference CTC size distribution using a computer; and assigning the disease condition of the cancer of the subject based on the comparing.